Choose On-Demand Treatment Berinert helps you with greater HAE control: self administration, on-demand.

"I always have an option to treat my attacks with me."
- Christie

Treat at the First Sign of Attack

Physicians around the world who are specialists in treating HAE have agreed that attacks should be treated as early as possible with an on-demand treatment such as C1-INH. In addition, every patient with HAE is a candidate for home therapy and self-administration training.11

Sometimes, early HAE symptoms appear that signal the onset of an HAE attack. It is important to treat at the first sign of an HAE attack. The sooner you treat, the sooner you will feel relief from the symptoms.

Berinert is the only on-demand C1-INH approved for self-administration after proper training by a healthcare professional. Self-administering Berinert simply allows you to treat your HAE at the first sign of an attack for fast relief.12

With Berinert self-administration you can reduce the length of your HAE attacks. You also have the flexibility to treat your HAE attacks wherever you happen to be.12

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Berinert features personalized, weight-based dosing for on-demand self-administration treatment that relieves symptoms quickly.

Individualized, weight-based dosing

Berinert is the only on-demand C1-INH hereditary angioedema treatment with weight-based dosing approved for self-administration that offers fast and sustained relief.

Because each dose of Berinert is calculated based on your weight, you use just the right amount of medicine —individualized for YOUR body. Because you use Berinert only to treat your HAE attacks, you only use the right amount of medicine when you need it.

Berinert uses weight-based dosing of 20 IU/kg body weight, which ensures you receive the correct dose of C1-INH during an attack. Talk to your doctor about establishing your dosing regimen.

"Within a half hour, or 45 minutes to an hour, the symptoms were completely gone."
- Stephanie

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Berinert is easy for you to keep it at home or carry with you because it can be stored for up to 30 months and does not require refrigeration.

Convenient room temperature storage

Berinert doesn’t require refrigeration and can be stored for up to 30 months, making it easy for you to keep it at home or carry with you.

"I can take it with me wherever I need it."
- Shari

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Save on Co-Pays: The Berinert Co-Pay BENefit™ may cover up to $12,000 of your eligible out-of-pocket expenses per year.

Download Enrollment Form »
continue to

Self-administered therapy is a convenient way to control your HAE. Reliable 24-hour support is available to provide training and answer questions.

Home Choose On-Demand Treatment

Important Safety Information

BERINERT®, C1 Esterase Inhibitor (Human), is used in adults and children to treat swelling and/or painful attacks of hereditary angioedema (HAE) affecting the abdomen, face or throat. The safety and efficacy of BERINERT in preventing HAE attacks have not been established.

Do not use BERINERT if you have experienced life-threatening allergic reactions or severe hypersensitivity to the product. Inform your healthcare provider of all medications you are taking and of any medical conditions, especially any history of blood-clotting problems.

Blood clots have occurred in patients receiving BERINERT. Tell your healthcare provider if you have a history of heart or blood vessel disease, stroke, or blood clots, or if you have thick blood, an indwelling catheter/access device in a vein, or have been immobile for some time. Certain medications, such as birth control pills, may also increase your risk of clotting problems.

Report to your physician or an emergency room any signs and symptoms of a blood clot, including pain and/or swelling or discoloration of an arm or leg, with warmth over affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In addition, report immediately any signs or symptoms of allergic reactions to BERINERT, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

If you have been trained to self-administer BERINERT, immediately prepare the prescribed dose at the first symptoms of an attack. Seek immediate medical attention and do not begin to self-administer if an HAE attack has progressed to a point where you will be unable to prepare or administer a dose of BERINERT.

If you self-administer to treat a laryngeal attack, immediately seek medical attention afterward. If you self-administer for an abdominal attack, inform your physician so that other possible causes can be ruled out.

Call your doctor right away if swelling is not controlled after use of BERINERT.

In clinical studies, the most serious adverse reaction reported in subjects who received BERINERT was an increased severity of the pain associated with HAE. In the placebo-controlled clinical trial, the most common adverse reaction reported more often among subjects who received BERINERT than those receiving placebo was dysgeusia (a bad taste in mouth). Tell your healthcare provider about any side effect that bothers you or does not go away.

Because BERINERT is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

Please see full prescribing information for BERINERT, including the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

CSL Behring
© 2018 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059(1)d